Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Varicella-Zoster Virus Infections in Patients Treated With Fingolimod: Risk Assessment and Consensus Recommendations for Management.
Copolymer 1 inhibits manifestations of graft rejection.
Assessment of Disease Activity in Multiple Sclerosis Phenotypes with Combined Gadolinium- and Superparamagnetic Iron Oxide-enhanced MR Imaging.
Disrupted balance of T cells under natalizumab treatment in multiple sclerosis.
Prospective memory, emotional valence, and multiple sclerosis.
FTY720 in patients with primary progressive multiple sclerosis (INFORMS)
The mystery of missing heritability: Genetic interactions create phantom heritability.
PI(3,5)P2 biosynthesis regulates oligodendrocyte differentiation by intrinsic and extrinsic mechanisms.
Long-Term Cost-Effectiveness Model of Interferon Beta-1b in the Early Treatment of Multiple Sclerosis in the United States.
B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis.
Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder.
Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multipl
Predictive value of early brain atrophy on response in patients treated with interferon β.
Ustekinumab.
The effects of long-term interferon- beta-1b treatment on cognitive functioning in multiple sclerosis: a 16-year longitudinal study.
Stem cells in autoimmune diseases: Implications for pathogenesis and future trends in therapy.
8th FENS Forum of Neuroscience
Polymorphisms in the receptor tyrosine kinase MERTK gene are associated with multiple sclerosis susceptibility.
Cytotoxicity, DNA cross-linking, and single strand breaks induced by activated cyclophosphamide and acrolein in human leukemia cells.
U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.
First proof for rituximab in IgG4-related disease
Bruxism and temporal bone hypermobility in patients with multiple sclerosis.
Immunosuppression with high-dose i.v. cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients.
Neuroprotective effects of recombinant T-cell receptor ligand in autoimmune optic neuritis in HLA-DR2 mice.
Remyelination therapy goes to trial for multiple sclerosis

Pages